RACK1 and Alzheimer disease: To determine whether IGF1‐IGF1R signaling is involved in AD pathology in vivo, we administered the IGF1R inhibitor PPP to both Rack1 WT/AD and Rack1 cKO/AD mice via intraperitoneal injection once every 2 days for 2 months (Figure7A).